HIV preexposure prophylaxis for adolescents and young adults.

View Abstract

PURPOSE OF REVIEW

The review describes the evidence for HIV preexposure prophylaxis (PrEP) with daily combined tenofovir disoproxil fumarate and emtricitabine for adolescents and young adults. Current recommendations are described, as are the unique medical, socioeconomic, and legal considerations regarding the use of PrEP for youth.

RECENT FINDINGS

PrEP with daily oral tenofovir disoproxil fumarate-emtricitabine has been shown to help prevent new HIV infection among adults at substantial risk. Evidence suggests a protective benefit of PrEP for youth at risk for HIV, although low adherence is emerging as a barrier to effective use.

SUMMARY

Effective use of antiretrovirals for PrEP represents a seminal development in HIV prevention efforts. Improving access and adherence to PrEP for youth has the potential to substantially reduce the incidence of HIV in this population.

Investigators
Abbreviation
Curr. Opin. Pediatr.
Publication Date
2017-08-29
Volume
29
Issue
4
Page Numbers
399-406
Pubmed ID
28598901
Medium
Print
Full Title
HIV preexposure prophylaxis for adolescents and young adults.
Authors
Allen E, Gordon A, Krakower D, Hsu K